KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Research & Development (2016 - 2025)

Pacira BioSciences (PCRX) has 16 years of Research & Development data on record, last reported at $37.5 million in Q4 2025.

  • For Q4 2025, Research & Development rose 56.73% year-over-year to $37.5 million; the TTM value through Dec 2025 reached $117.3 million, up 43.81%, while the annual FY2025 figure was $117.3 million, 43.81% up from the prior year.
  • Research & Development reached $37.5 million in Q4 2025 per PCRX's latest filing, up from $26.3 million in the prior quarter.
  • Across five years, Research & Development topped out at $37.5 million in Q4 2025 and bottomed at $11.6 million in Q3 2021.
  • Average Research & Development over 5 years is $20.8 million, with a median of $19.4 million recorded in 2022.
  • Peak YoY movement for Research & Development: skyrocketed 109.04% in 2022, then dropped 28.38% in 2023.
  • A 5-year view of Research & Development shows it stood at $15.5 million in 2021, then increased by 12.83% to $17.5 million in 2022, then rose by 11.19% to $19.5 million in 2023, then increased by 22.78% to $23.9 million in 2024, then surged by 56.73% to $37.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $37.5 million in Q4 2025, $26.3 million in Q3 2025, and $28.2 million in Q2 2025.